Just received an alert entitled, 'Inverness is poised for a breakout'.
It goes on to say that Inverness is the world leader in point of care diagnostics, and its global market is estimated at $4.5 billion. It says that its test are built for rapid deployment in homes and doctors' offices. With a needle prick, it can identify everything from cardiac conditions to infectious disease to cancer. Sales are growing at 22% in the midst of the current slowdown. With the population aging, more patients are demanding faster, more accurate testing. Not a bad partner to be associated with. I am not making a recommendation on the stock, but it is nice to know the potential that awaits recaf. Now I'll turn it over to the bashers.
